Bard Financial Services Inc. bought a new position in shares of Sanofi (NASDAQ:SNY) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 16,300 shares of the company’s stock, valued at approximately $792,000.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNY. Reby Advisors LLC bought a new stake in Sanofi during the 4th quarter worth approximately $35,000. Arkadios Wealth Advisors bought a new stake in shares of Sanofi during the fourth quarter valued at approximately $36,000. Charter Oak Capital Management LLC bought a new stake in shares of Sanofi during the fourth quarter valued at approximately $40,000. JJJ Advisors Inc. raised its position in shares of Sanofi by 193.8% during the fourth quarter. JJJ Advisors Inc. now owns 852 shares of the company’s stock valued at $41,000 after buying an additional 562 shares during the last quarter. Finally, Accel Wealth Management bought a new stake in shares of Sanofi during the fourth quarter valued at approximately $43,000. Institutional investors own 6.93% of the company’s stock.
SNY stock opened at $49.97 on Thursday. The firm has a fifty day moving average price of $47.96 and a 200 day moving average price of $48.74. Sanofi has a fifty-two week low of $42.80 and a fifty-two week high of $55.00. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.38 and a current ratio of 1.85. The firm has a market cap of $125.82 billion, a PE ratio of 21.35, a price-to-earnings-growth ratio of 1.90 and a beta of 0.55.
The company also recently disclosed an annual dividend, which will be paid on Wednesday, May 26th. Shareholders of record on Tuesday, May 4th will be paid a dividend of $1.9061 per share. This represents a yield of 3.2%. This is a positive change from Sanofi’s previous annual dividend of $1.21. The ex-dividend date of this dividend is Monday, May 3rd. Sanofi’s payout ratio is presently 35.24%.
Several equities research analysts have recently issued reports on SNY shares. UBS Group reiterated a “buy” rating on shares of Sanofi in a research report on Tuesday, January 19th. Barclays reiterated an “equal weight” rating on shares of Sanofi in a research report on Tuesday. Morgan Stanley reiterated an “overweight” rating on shares of Sanofi in a research report on Wednesday, February 10th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Sanofi in a research report on Friday, January 15th. They set a “sell” rating on the stock. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. Sanofi has a consensus rating of “Hold” and a consensus price target of $53.00.
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura.
See Also: Strike Price
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.